Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 4/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428686 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| Hydrochloric Acid SCHEMBL6767466 | 0.98 | HTR2C (0.45) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL2452698 | 0.89 | HTR2C (0.37) | HTR2CCHRNB2CHRNA4PNMT | |
| SCHEMBL2342848 | 0.86 | CHRNB2 (0.48) | HTR2CCHRNB2CHRNA4CHRM4CHRM5 | |
| SCHEMBL29772412 | 0.84 | POLB (0.43) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL160968 | 0.84 | POLB (0.43) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| Hydrochloric Acid SCHEMBL6438259 | 0.84 | CHRNB2 (0.47) | HTR2CCHRNB2CHRNA4CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL31126075 | 0.82 | POLB (0.42) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| Hydrochloric Acid SCHEMBL7009520 | 0.82 | POLB (0.42) | HTR2CCHRNB2CHRNA4PNMTCD44 | |
| SCHEMBL1195270 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175998-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS, LTD. (GB) | 2024-08-29 | — | — | WO | claimed |
| WO-2024175999-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2024-08-29 | — | — | WO | claimed |
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-09-06 | — | — | US | claimed |
| EP-3717488-B1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-09-29 | — | — | EP | claimed |
| EP-3717488-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | Dart NeuroScience, LLC (US) | 2020-10-07 | — | — | EP | claimed |
| CN-111655695-A | Substituted furopyrimidines as PDE1 inhibitors | 达特神经科学有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-105712974-B | Certain amino-pyrimidines, compositions thereof and methods of use thereof | 赛特凯恩蒂克公司 | 2020-07-31 | — | — | CN | claimed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | claimed |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2010-06-03 | — | — | US | claimed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | claimed |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-07 | — | — | US | disclosed |
| US-20250381243-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| WO-2004055011-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004055010-A2 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004055016-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | HTR2C 2604/4885CHRNB2 397/4885CHRNA4 69/4885 |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | HTR2C 103/4885CHRNB2 21/4885CHRNA4 30/4885 |
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | PDE4A, PDE5A, PDE3A | HTR2C 2093/4885CHRNB2 1240/4885CHRNA4 1346/4885 |
| US-12473295-B2 | Substituted straight chain spiro derivatives | MLLT1, MEN1, MLLT3 | HTR2C 4695/4885CHRNB2 4859/4885CHRNA4 4830/4885 |
| US-20250381243-A1 | HETEROCYCLES AND USES THEREOF | TP53, KRAS, HRAS | HTR2C 2410/4885CHRNB2 4460/4885CHRNA4 4851/4885 |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | TRPV1, TRPA1, TRPV2 | HTR2C 166/4885CHRNB2 985/4885CHRNA4 688/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2C 4531/4885CHRNB2 4879/4885CHRNA4 4869/4885 |
| US-20260125387-A1 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | MLLT1, MEN1, MLLT3 | HTR2C 2877/4885CHRNB2 3931/4885CHRNA4 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.